US Merck & Co., operating as MSD outside the US and Canada, and Chinese biopharmaceutical company Hansoh Pharma have entered into an exclusive global license agreement...
US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific...
Mestag Therapeutics, a Cambridge, UK-headquartered biotech company working on new insights into fibroblast-immune interactions, has signed a license and collaboration...
MSD Animal Health, a division of Merck & Co., announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for €1...
US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity...
Merck & Co. (MSD) and Caraway Therapeutics announced that the companies have agreed Merck & Co., through a subsidiary, will acquire Caraway Therapeutics for a total...
Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where...
